Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. (01349.HK) has announced that the Phase I clinical study of the injection FZ-AD005 antibody conjugate (i.e., anti-DLL3 antibody conjugate BB05) developed by the company for the treatment of late-stage solid tumors has successfully enrolled its first subject.
复旦张江(01349.HK)：注射用FZ-AD005抗体偶联剂用于治疗晚期实体瘤I期临床试验完成首例受试者入组
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. (01349.HK) announced completion of enrollment of the first participant in Phase I clinical trial of injectable FZ-AD005 antibody conjugate for the treatment of advanced solid tumors.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.